[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100183173":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":19,"locations":25,"responsibleParty":48,"collaborators":51,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":19,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":19,"maxAge":19,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":54,"whyStopped":19,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Fondazione Onlus Camillo De Lellis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"standard intravenous immunoglobulin","EXPERIMENTAL","Single arm evaluation of neurological consequences of congenital CMV infection in comparison with historical untreated controls.",[13],"Biological: standard intravenous immunoglobulin",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Human standard intravenous immunoglobulin (IVIG), 0.5 g\u002FKg of body weight, monthly after confirmation of primary gestational CMV infection",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Giustino Parruti, MD, PhD","Azienda Sanitaria Locale di Pescara","PRINCIPAL_INVESTIGATOR",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Infection Disease Unit, Pescara General Hospital, Pescara, Italy","RECRUITING","Pescara","Abruzzo","65124","Italy","IT",{"type":35,"coordinates":36},"Point",[37,38],14.20283,42.4584,{"lat":38,"lon":37},[41,45],{"name":42,"role":43,"phone":19,"phoneExt":19,"email":44},"Francesca D'Arcangelo, MD","CONTACT","francescadarcangelo@yahoo.it",{"name":46,"role":43,"phone":19,"phoneExt":19,"email":47},"Antonina Sciacca, Secretary","a.sciacca@virgilio.it",{"type":24,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":23,"oldNameTitle":19,"oldOrganization":19},"Dr. Giustino Parruti","MD, PhD",[52,55],{"name":53,"class":54},"Regione Abruzzo, Italy","UNKNOWN",{"name":23,"class":6},"100183173","evaluation-of-the-safety-and-efficacy-of-standard-intravenous-immunoglobulins-in-pregnant-women-with-primary-cytomegalovirus-infection-100183173",false,"NCT01659684","Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection","Inclusion Criteria:\n\n* Pregnant women with confirmed primary CMV infection at any stage of gestation.\n\nExclusion Criteria:\n\n* Pregnant women with falsely positive CMV IgM antibodies or high (\\>40%) CMV IgG avidity indexes","FEMALE",{"count":64,"type":65},300,"ESTIMATED","INTERVENTIONAL",[68],"NA","Because the potential benefit of standard intravenous immunoglobulins (IVIG) - obtained from unselected donor pools including a varying proportion of donors previously exposed to CMV - has not yet been explored in pregnant women, the investigators performed a longitudinal prospective study on the possible efficacy of IVIG for prevention or therapy of fetal CMV infection.",[71],"Cytomegalovirus Congenital Infection",[73,74,75,76,77],"congenital CMV infection","standard immunoglobulins","immunoglobulin therapy","IgG CMV avidity index","Cytomegalovirus","2012-08-03",{"date":80,"type":65},"2012-08-08",{"date":82,"type":19},"2010-10",{"date":84,"type":65},"2014-11",{"name":5,"class":6},1]